CY-2010: NCI will start a Phase I/II trial

Cytel Corp. (CYTL), San Diego Product: CY-2010 peptide derived from the MAGE-3 tumor marker, which directs cytotoxic T lymphocytes to cells bearing the antigen. Indication: Solid tumors including mela...